Evidence map›Paper›PMID 42655728›Full record

ArticleViruses2026

Maraviroc Inhibits SARS-CoV-2 Through Variant-Dependent Effects on Viral Entry and Mpro Activity Using Single-Round Infectious Particle and Virus-like Particle Models.

Uyen Nguyen Phuong Le, Po-Ju Chen, Li-Wei Chu, Jane Cynthia Arifin, Chih-Hao Chen, Yu-Hsuan Chen, Wen-Chi Su, Po-Ren Hsueh, Yueh-Hsin Ping, Cheng-Wen Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Uyen Nguyen Phuong LeDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan.ORCID 0009-0005-6784-6646
Po-Ju ChenDepartment and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Li-Wei ChuDepartment and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.ORCID 0000-0002-6291-4436
Jane Cynthia ArifinDepartment and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Chih-Hao ChenDivision of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan.
Yu-Hsuan ChenDepartment and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.ORCID 0009-0008-2311-5480
Wen-Chi SuGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404328, Taiwan.
Po-Ren HsuehDivision of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan.
Yueh-Hsin PingDepartment and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.ORCID 0000-0003-2604-9913
Cheng-Wen LinDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan.ORCID 0000-0003-0165-2652

Funding

National Science and Technology Council NSTC112-2320-B-039-054-MY3
6 · The paper itself

Abstract

Maraviroc (MVC), a CCR5 antagonist, has been proposed as a potential antiviral agent against SARS-CoV-2; however, its mechanism of action across viral variants remains unclear. Here, we evaluated the antiviral activity of MVC against SARS-CoV-2 wild-type (WT) and Omicron BA.1 variants using single-round infectious particles (SRIPs), virus-like particles (VLPs), and cell-based assays, with a focus on its impact on viral entry and Mpro function. MVC potently inhibited infection of both WT and BA.1 SRIPs in Vero E6 cells, exhibiting EC

Indexed as

Antiviral AgentsMaravirocSARS-CoV-2Virus InternalizationAnimalsChlorocebus aethiopsEndocytosisHumansVero CellsVirionAntiviral AgentsMaravirocmain protease (Mpro)maravirocomicron variantSARS-CoV-2single-round infectious particle (SRIP)spike protein (S)virus-like particles (VLP)

Identifiers

PMID42655728
PMCPMC13517540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.